Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that…
SAN DIEGO & EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Cambridge, Massachusetts-based…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) has filed an…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Christel Iffland, Ph.D. as a Vice President of Antibody Technologies…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO…
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc. Under the license…
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able…